Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNorthwestern University
About this trial
This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages. CKD damage to the kidneys, AR and HCV all lower the body's ability to function properly. Early detection of these conditions could assist with successful treatment and possibly lead to less repeat organ transplants.
Eligibility criteria
Qualifiers
Male and female recipients of all races, ≥18 years of age.
Patients undergoing primary or subsequent living or deceased donor liver transplantation.
Subject and/or guardian must be able to provide informed consent.
Subject and/or guardian must be able to comply with the study protocol.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Northwestern University
Lead sponsor
The Scripps Research Institute
Collaborator
Source ClinicalTrials.gov